MK-1308
Total Payments
$6.0M
Transactions
1,470
Doctors
7
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $893,271 | 148 | 4 |
| 2019 | $1.3M | 215 | 5 |
| 2018 | $3.7M | 885 | 6 |
| 2017 | $124,237 | 222 | 5 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.8M | 1,316 | 96.6% |
| Consulting Fee | $206,255 | 150 | 3.4% |
| Food and Beverage | $350.38 | 4 | 0.0% |
Payments by Type
Research
$5.8M
1,316 transactions
General
$206,605
154 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors | Merck Sharp & Dohme Corporation | $5.0M | 0 |
| A Phase 1,2 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors | Merck Sharp & Dohme Corporation | $798,934 | 0 |
| A Phase 1 , 2 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors | Merck Sharp & Dohme Corporation | $13,274 | 0 |
Top Doctors Receiving Payments for MK-1308
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Joyce Sherman | — | Plainfield, NJ | $5.8M | 1,351 |
| , M.D | Diagnostic Radiology | Philadelphia, PA | $61,065 | 31 |
| , M.D | Diagnostic Radiology | Upland, PA | $50,694 | 35 |
| , M.D | Diagnostic Radiology | Kinnelon, NJ | $40,890 | 34 |
| , M.D | Diagnostic Radiology | Kendall Park, NJ | $5,400 | 13 |
| , MD | Nuclear Radiology | Abington, PA | $3,000 | 1 |
| , MD | Medical Oncology | New Haven, CT | $487.50 | 1 |
| , MD | Hematology | Hackensack, NJ | $350.38 | 4 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $6.0M
- Total Doctors 7
- Transactions 1,470
About MK-1308
MK-1308 is a drug associated with $6.0M in payments to 7 healthcare providers, recorded across 1,470 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2020. In 2020, $893,271 was paid across 148 transactions to 4 doctors.
The most common payment nature for MK-1308 is "Unspecified" ($5.8M, 96.6% of total).
MK-1308 is associated with 3 research studies, including "A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors" ($5.0M).